A century-old mitochondria-targeting compound that acts as an electron carrier to improve ATP production and cognitive function.
Methylene Blue (3,7-bis(dimethylamino)phenothiazin-5-ium chloride) is a synthetic compound with over 130 years of medical history, originally synthesized in 1876 and used as the first synthetic drug in medicine. It is FDA-approved for the treatment of methemoglobinemia and has been used as an antimalarial, antiseptic, and diagnostic agent. At low doses (0.5-4 mg/kg), Methylene Blue acts as an alternative electron carrier in the mitochondrial electron transport chain, improving ATP production efficiency and reducing the formation of reactive oxygen species. Multiple human studies have demonstrated cognitive enhancement effects, including improved memory consolidation, attention, and processing speed. Research has also shown potential neuroprotective effects relevant to Alzheimer’s disease, with Methylene Blue inhibiting tau aggregation and reducing amyloid toxicity. The compound’s unique redox cycling properties allow it to function as both an electron donor and acceptor, making it a versatile mitochondrial enhancer.
* Benefits based on preclinical/animal research unless otherwise noted.
At low doses, Methylene Blue acts as a redox cycler in the mitochondrial electron transport chain. It accepts electrons from NADH (at Complex I) and donates them directly to cytochrome c (between Complex III and IV), effectively bypassing Complex I and III dysfunction. This alternative electron transport pathway increases ATP production, reduces the formation of superoxide and other reactive oxygen species, and improves overall mitochondrial efficiency. Methylene Blue also inhibits nitric oxide synthase (NOS) at low doses, reducing the nitric oxide-mediated inhibition of cytochrome c oxidase (Complex IV). Additionally, it has been shown to inhibit tau protein aggregation and reduce amyloid-beta toxicity through direct binding interactions, suggesting neuroprotective mechanisms beyond mitochondrial enhancement. The compound crosses the blood-brain barrier efficiently, concentrating in brain tissue where its mitochondrial effects are most relevant for cognitive function.
Protocol Notes: Low doses (0.5–4 mg/kg) are beneficial; high doses (>10 mg/kg) can be harmful. Take in the morning. Blue-green urine is normal and expected.
Store at room temperature, away from light.
When sourcing Methylene Blue (Capsule) for research purposes, the following quality benchmarks should be verified before use.
Store at room temperature, away from light.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Moderate Evidence — Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited.
Peptides commonly used alongside Methylene Blue (Capsule) for synergistic effects.
Comprehensive Nootropic Stack
A comprehensive nootropic stack combining synaptogenesis, anxiolysis, BDNF upregulation, and cellular energy for peak cognitive performance.
Learn More: Dihexa + Selank + Semax + NAD+ (Capsule)Angiotensin IV Analog / Nootropic
An angiotensin IV analog reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
Learn More: Dihexa (Capsule)